Since GLP-1 RAs can slow down the movement of food through the digestive system, this may result in food remaining in the stomach for longer periods than usual, leading to symptoms characteristic of gastroparesis such as nausea, vomiting, bloating, and abdominal discomfort
Main methods Assessment included magnesium sulfate (560 mg/kg intraperitoneally)-induced muscle weakness, muscle and brain lesions, hypermagnesemia, hyperkalaemia, increased serum enzyme values assessed in rats during and at the end of a 30-min period and medication (given intraperitoneally/kg at 15 min before magnesium) [BPC 157 (10 g, 10 ng), l-NAME (5 mg), l-arginine (100 mg), alone and/or together]
Mertens turned to injectable Zepbound when he regained weight after the end of the Wegovy pill clinical trial
References Lopes-Coelho, F., Gouveia-Fernandes, S., Gonalves, L
The efficacy and safety of -nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
The no-subscription approach addresses one of the biggest pain points in GLP-1 telehealth